RadNet, Inc. (RDNT)

RadNet's stock price has been influenced by several events in the past six months. As of January 6, 2026, the share price was $77.36, representing a 6.81% increase from January 7, 2025. The stock has experienced volatility, with a 52-week range between approximately $45.00 and $85.84. RadNet reported record quarterly revenue in Q3 2025, exceeding analyst expectations, and revised its 2025 financial guidance upwards. Several analysts have updated their ratings and price targets for RDNT. RadNet's shares fell after a short-seller report questioned the company's AI business and growth metrics. RadNet announced the acquisition of Radiology Regional, adding 13 imaging centers and projected to contribute approximately $100 million in revenue in 2026.

Demand for RadNet's products and services can experience some seasonality, particularly influenced by external factors such as severe weather events. Despite these short-term fluctuations, there is a broader trend of increasing demand for diagnostic imaging services, driven by an aging U.S. population, a growing emphasis on preventative screening, and new technological advancements. The approval of new Alzheimer's drugs is another identified growth driver for RadNet's imaging services.

RadNet, Inc. is a leading American radiology firm specializing in outpatient diagnostic imaging services, operating in the Healthcare sector, specifically in the Diagnostics & Research and Medical Specialties industries. It is the largest operator of freestanding, fixed-site diagnostic imaging centers in the United States, offering a comprehensive range of services including MRI, CT, PET, nuclear medicine, mammography, ultrasound, diagnostic radiology, and fluoroscopy. RadNet develops and sells computerized systems for digital image distribution and deploys AI suites to enhance radiologist interpretation and offers solutions for prostate cancer screening.

RadNet's geographic footprint spans across several states in the United States. As of 2025, the company owns and/or operates over 400 imaging centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, and Texas. Recent expansions include the acquisition of 13 imaging centers in the Houston, Texas, metropolitan area in April 2024, and the acquisition of Radiology Regional in January 2026, adding 13 imaging centers across Southwest Florida.

RadNet generally maintains a positive brand reputation within the investment community, reflected in a consensus "Moderate Buy" rating from analysts. The company's Enhanced Breast Cancer Detection program, which uses AI to read mammograms, has been cited as a positive innovation. However, RadNet's reputation faced a challenge in December 2025 when a short-seller report questioned the efficacy and revenue contribution of its AI business and alleged inflated "same-center" revenue growth figures, leading to a drop in the stock price.

RadNet, Inc. has significant institutional ownership, with 667 institutional owners and shareholders holding a total of 94,928,075 shares. Institutional investors collectively own over 50% of the company. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, iShares Core S&P Small-Cap ETF, Beck Mack & Oliver Llc, Rtw Investments, Lp, State Street Corp, Price T Rowe Associates Inc /md/, Allspring Global Investments Holdings, LLC, and Geode Capital Management, Llc. Individual insiders also hold a significant stake.